Malaria and Sickle Cell Disease Treatment Market, By Disease, By Drug Type, By Route of Administration, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
보고서 하이라이트
말라리아 및 겸상적혈구병 치료제(Malaria and Sickle Cell Disease Treatment) 시장 규모는 2023년 56억 1,136만 달러였으며, 2024년부터 2032년까지 CAGR 25.9%로 추이하며 확대 할 것으로 예상됩니다.
말라리아 및 겸상적혈구병 치료제 시장-시장 역학
높은 유병률에서 말라리아와 겸상 적혈구증의 치료 진보
말라리아 및 겸상적혈구병 치료제의 진보는 높은 병리학 속에서 이러한 질병으로 인한 세계의 건강에 중요한 부담을 다루는 데 매우 중요합니다. 예를 들어, 세계보건기구(WHO)에 따르면 말라리아는 세계에서 연간 2억 명 이상이 영향을 받고 있습니다. 겸상 적혈구증 연합에 따르면, 겸상 적혈구증(SCD)을 앓고 있는 어린이는 세계에서 연간 30만 명이 있다고 추정되고 있습니다. 이 수는 2050년까지 40만명으로 증가할 것으로 예상됩니다. 이에 대해 국립위생연구소(NIH)와 빌앤멜린다 게이츠재단 등의 조직은 혁신적인 치료법 및 예방전략 개발을 목적으로 한 연구개발에 투자하고 있습니다. 최근의 획기적인 사건으로는 타페노킨과 같은 새로운 항 말라리아 약물의 승인이나 겸상 적혈구증에 대한 유망한 유전자 편집 요법의 출현 등이 있으며, 건강 관리의 진보가 세계에 걸린 환자의 부담을 줄일 가능성을 보여줍니다.
말라리아 및 겸상적혈구병 치료제 시장-주요 통찰력
우리의 리서치 애널리스트 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 25.9%의 CAGR로 매년 성장할 것으로 예측됩니다.
질병별로는 겸상적혈구증이 2023년 최대 시장 점유율을 나타냈습니다.
약물 유형별로 2023년에 항말라리아 약물이 주요 유형이었습니다.
지역별로는 아시아 태평양이 2023년 매출에서 최고였습니다.
말라리아 및 겸상적혈구병 치료제 시장-세분화 분석 :
세계의 말라리아와 겸상 적혈구 치료 시장은 질병, 약물 유형, 투여 경로 및 지역에 따라 세분화됩니다.
말라리아 및 겸상적혈구병 치료제 시장은 질병에 따라 두 가지 범주로 나뉩니다. 말라리아와 겸상 적혈구증입니다. 말라리아는 환자 수 증가와 내성균 대책으로서 즉효성이 있는 약제를 우선해, 환자수가 많은 지역에 중점을 두고 있습니다. 한편, 겸상 적혈구증은 만성 증상의 장기적인 관리와 환자의 QOL 향상을 목표로합니다.
시장은 약물의 유형에 따라 세 가지 범주로 나뉩니다 : 항 말라리아 약물, 통증 관리 약물, 질병 변형 치료. 항 말라리아 약물은 기생충 자체를 표적으로하는 것으로 압도적인 점유율을 차지합니다. 통증 관리 약물은 겸상 적혈구증의 주요 증상을 다룹니다. 가장 유망한 분야는 질병 수정 요법으로 질병 진행을 지연시키고 장기적인 결과를 개선시킬 수 있습니다.
말라리아 및 겸상적혈구병 치료제 시장-지리적 통찰
말라리아 및 겸상적혈구병 치료제 시장은 다양한 패턴을 보여주며, 특히 사하라 이남의 아프리카와 동남아시아의 일부 등 이러한 질병의 영향을 크게 받고 있는 지역에 큰 활동이 집중되고 있습니다. 말라리아가 만연하고 겸상 적혈구증의 유병률이 높은 아프리카에서는 Roll Back Malaria Partnership(말라리아 롤백 파트너십)이나 국가 말라리아 대책 프로그램과 같은 대처가 치료나 개입에 대한 수요를 촉진하고 있다 합니다. 또한 건강 관리에 대한 액세스를 개선하고 의료 인프라를 강화하는 노력이 이러한 지역 시장 성장에 기여하고 있습니다. 동남아시아에서는 인도나 인도네시아 같은 나라들이 말라리아의 심각한 문제를 다루고 있으며, 인도나 나이지리아와 같은 인구가 많은 나라에서는 겸상 적혈구증이 여전히 우려되고 있습니다. 이 지역은 말라리아와 겸상 적혈구 치료제의 주요 시장이며, 이러한 질병과 싸우고 건강 관리에 대한 접근과 제공을 개선하기위한 지속적인 노력이 시장 확대의 원동력이되었습니다.
말라리아 및 겸상적혈구병 치료제 시장-경쟁 구도 :
말라리아와 겸상 적혈구 치료 시장은 Pfizer, Novartis, Sanofi와 같은 제약 선도적인 전장입니다. 이들 기업은 신약 출시(예 : Novartis의 1일 1회 투여의 말라리아 치료제), 유망 기업의 인수(예 : Pfizer에 의한 겸상 적혈구 치료의 리더, Global Blood Therapeutics의 인수), 차세대 솔루션을 위한 R&D에 많은 투자와 같은 전략을 통해 지속적으로 우위를 차지하기 위해 혁신을 계속하고 있습니다. 이러한 치열한 경쟁은 환자에게 좋습니다. 왜냐하면 개선된 치료제, 보다 용이한 치료법, 그리고 소망하면, 양 질환에 있어서 미충족 요구를 해결하는 획기적인 치료법이 잇달아 만들어지기 때문입니다.
목차
제1장 말라리아 및 겸상적혈구병 치료제 시장 개요
제2장 주요 요약
제3장 말라리아 및 겸상적혈구병 치료제의 주요 시장 동향
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 시장의 미래 동향
제4장 말라리아 및 겸상적혈구병 치료제 산업 연구
- PEST 분석
- Porter's Five Forces 분석
- 성장 전망 맵핑
- 규제 프레임워크 분석
제5장 말라리아 및 겸상적혈구병 치료제 시장 : COVID-19의 영향 분석
- COVID-19 이전의 영향 분석
- COVID-19 이후의 영향 분석
제6장 말라리아 및 겸상적혈구병 치료제 시장 상황
- 말라리아 및 겸상적혈구병 치료제 시장 점유율 분석(2023년)
- 주요 제조업체별 분석 데이터
제7장 말라리아 및 겸상적혈구병 치료제 시장-질환별
- 개요
- 질병별 부문 점유율 분석
- 말라리아
- 겸상적혈구증
제8장 말라리아 및 겸상적혈구병 치료제 시장-약제 유형별
- 개요
- 약제 유형별 부문 점유율 분석
- 항말라리아 약
- 통증 관리 약
- 질환 수식 요법
- 기타
제9장 말라리아 및 겸상적혈구병 치료제 시장-투여 경로별
제10장 말라리아 및 겸상적혈구병 치료제 시장-지역별
- 소개
- 북미
- 유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
- 아시아 태평양
- 개요
- 아시아 태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
- 남미
- 개요
- 남미의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타
제11장 주요 벤더 분석-말라리아 및 겸상적혈구병 치료제 산업
- 경쟁 대시보드
- 기업 프로파일
- AbbVie Inc.
- Alexion Pharmaceuticals, Inc.(acquired by AstraZeneca)
- Bluebird bio Inc.
- Celgene Corporation(acquired by Bristol Myers Squibb)
- Emmaus Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson &Johnson
- MacroGenics, Inc.
- Merck &Co., Inc.
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Sobi
- Vertex Pharmaceuticals Incorporated
- 기타
제12장 애널리스트의 전방위 전망
LYJ
REPORT HIGHLIGHT
Malaria and Sickle Cell Disease Treatment Market size was valued at USD 5,611.36 million in 2023, expanding at a CAGR of 25.9% from 2024 to 2032.
The Malaria and Sickle Cell Disease Treatment Market refers to the industry segment focused on the development and provision of therapies and interventions for combating malaria and managing sickle cell disease. The persistent global burden of malaria, particularly in tropical and subtropical regions, driving investments in research and development for innovative treatments and preventive measures. Additionally, the growing prevalence of sickle cell disease, especially in regions with high malaria transmission rates, further fuels market growth, prompting efforts to enhance disease management and develop curative therapies. However, restraints include the challenge of drug resistance in malaria treatment and the complexity of sickle cell disease management, compounded by limited access to healthcare in resource-constrained settings. Nevertheless, opportunities abound with advancements in precision medicine and gene therapy, promising novel approaches for personalized treatment and potential cures, thereby driving innovation and market expansion in the malaria and sickle cell disease treatment landscape.
Malaria and Sickle Cell Disease Treatment Market- Market Dynamics
Advancements in Treating Malaria and Sickle Cell Disease Amidst High Prevalence
Advancements in treating malaria and sickle cell disease amidst high prevalence are crucial for addressing the significant global health burden posed by these conditions. For instance, according to the World Health Organization (WHO), malaria affects over 200 million people worldwide annually. According to the Sickle Cell Disease Coalition, an estimated 300,000 children are born annually with sickle cell disease (SCD) worldwide. This number is expected to increase to 400,000 by 2050. In response, organizations like the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation are investing in research initiatives aimed at developing innovative treatments and preventive strategies. Recent breakthroughs include the approval of new antimalarial drugs like tafenoquine and the emergence of promising gene-editing therapies for sickle cell disease, underscoring the potential of advancements in healthcare to alleviate the burden of these diseases on affected populations worldwide.
Malaria and Sickle Cell Disease Treatment Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 25.9% over the forecast period (2024-2032)
Based on Disease segmentation, Sickle Cell Disease was predicted to show maximum market share in the year 2023
Based on Drug Type segmentation, Antimalarial Drugs was the leading type in 2023
Based on region, Asia Pacific was the leading revenue generator in 2023
Malaria and Sickle Cell Disease Treatment Market- Segmentation Analysis:
The Global Malaria and Sickle Cell Disease Treatment Market is segmented based on Disease, Drug Type, Route of Administration, and Region.
The market is divided into two categories based on Disease: Malaria and Sickle cell disease. Malaria prioritizes fast-acting drugs to combat rising cases and resistance, focusing on high-burden regions. Conversely, the sickle cell segment targets long-term management of chronic symptoms and improving patients' quality of life.
The market is divided into three categories based on Drug Type: Antimalarial Drugs, Pain Management Drugs, and Disease-Modifying Therapies. Antimalarial drugs dominate, targeting the parasite itself. Pain management drugs address a key symptom of sickle cell disease. The most promising segment is disease-modifying therapies, offering the potential to slow disease progression and improve long-term outcomes.
Malaria and Sickle Cell Disease Treatment Market- Geographical Insights
The Malaria and Sickle Cell Disease Treatment Market exhibits diverse patterns, with significant activity concentrated in regions disproportionately affected by these diseases, particularly in sub-Saharan Africa and parts of Southeast Asia. In Africa, where malaria is endemic and sickle cell disease prevalence is high, initiatives like the Roll Back Malaria Partnership and national malaria control programs drive demand for treatments and interventions. Additionally, efforts to improve access to healthcare and strengthen healthcare infrastructure contribute to market growth in these regions. In Southeast Asia, countries like India and Indonesia grapple with significant malaria burdens, while sickle cell disease remains a concern in countries with large populations such as India and Nigeria. These regions collectively represent key markets for malaria and sickle cell disease treatments, with opportunities for market expansion driven by ongoing efforts to combat these diseases and improve healthcare access and delivery.
Malaria and Sickle Cell Disease Treatment Market- Competitive Landscape:
The Malaria and Sickle Cell Disease treatment market is a battlefield for pharmaceutical giants like Pfizer, Novartis, and Sanofi. These companies are constantly innovating to stay ahead, with strategies like launching new drugs (e.g., Novartis' once-daily malaria treatment), acquiring promising companies (e.g., Pfizer's acquisition of sickle cell therapy leader Global Blood Therapeutics), and investing heavily in R&D for next-generation solutions. This fierce competition is good news for patients, as it translates into a constant flow of improved medications, easier treatment regimens, and hopefully, breakthroughs that address unmet needs in both diseases.
Recent Developments:
In September 2022, Vertex Pharmaceuticals and CRISPR Therapeutics launched a gene therapy called "exa-cel" for treating sickle cell disease. The treatment involves permanently changing DNA in a patient's blood cells to help the body produce a fetal form of hemoglobin, which is naturally present at birth but switches to an adult form that is defective in people with sickle cell disease.
In December 2023, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
AbbVie Inc.
Alexion Pharmaceuticals, Inc. (acquired by AstraZeneca)
Bluebird Bio Inc.
Celgene Corporation (acquired by Bristol Myers Squibb)
Emmaus Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
GlaxoSmithKline plc
Johnson & Johnson
MacroGenics, Inc.
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
Sanofi S.A.
Sobi
Vertex Pharmaceuticals Incorporated
Others
GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032
- Malaria
- Sickle cell disease
GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
- Antimalarial Drugs
- Pain Management Drugs
- Disease-Modifying Therapies
- Other
GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Malaria and Sickle Cell Disease Treatment Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Malaria and Sickle Cell Disease Treatment Market Snippet by Disease
- 2.1.2. Malaria and Sickle Cell Disease Treatment Market Snippet by Drug Type
- 2.1.3. Malaria and Sickle Cell Disease Treatment Market Snippet by Route of Administration
- 2.1.4. Malaria and Sickle Cell Disease Treatment Market Snippet by Country
- 2.1.5. Malaria and Sickle Cell Disease Treatment Market Snippet by Region
- 2.2. Competitive Insights
3. Malaria and Sickle Cell Disease Treatment Key Market Trends
- 3.1. Malaria and Sickle Cell Disease Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Malaria and Sickle Cell Disease Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Malaria and Sickle Cell Disease Treatment Market Opportunities
- 3.4. Malaria and Sickle Cell Disease Treatment Market Future Trends
4. Malaria and Sickle Cell Disease Treatment Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Malaria and Sickle Cell Disease Treatment Market: COVID-19 Impact Analysis
- 5.1. Pre-COVID-19 Impact Analysis
- 5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments
6. Malaria and Sickle Cell Disease Treatment Market Landscape
- 6.1. Malaria and Sickle Cell Disease Treatment Market Share Analysis, 2023
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Malaria and Sickle Cell Disease Treatment Market - By Disease
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Disease, 2023 & 2032 (%)
- 7.1.2. Malaria
- 7.1.3. Sickle cell disease
8. Malaria and Sickle Cell Disease Treatment Market - By Drug Type
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 8.1.2. Antimalarial Drugs
- 8.1.3. Pain Management Drugs
- 8.1.4. Disease-Modifying Therapies
- 8.1.5. Other
9. Malaria and Sickle Cell Disease Treatment Market - By Route of Administration
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Parenteral
10. Malaria and Sickle Cell Disease Treatment Market- By Geography
- 10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
- 10.2. North America
- 10.2.1. Overview
- 10.2.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
- 10.2.7.1. Overview
- 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.2.7.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.2.7.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
- 10.2.8.1. Overview
- 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.2.8.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.2.8.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3. Europe
- 10.3.1. Overview
- 10.3.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
- 10.3.7.1. Overview
- 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.7.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.7.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
- 10.3.8.1. Overview
- 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.8.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.8.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.8.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
- 10.3.9.1. Overview
- 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.9.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.9.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.10. France
- 10.3.10.1. Overview
- 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.10.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.10.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
- 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.11.2. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.11.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.11.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
- 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.12.2. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.12.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.12.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
- 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.13.2. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.13.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
- 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.14.2. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.14.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.14.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
- 10.3.15.1. Overview
- 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.15.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.15.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.7. India
- 10.4.7.1. Overview
- 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.7.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.7.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.7.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.8. China
- 10.4.8.1. Overview
- 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.8.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.8.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
- 10.4.9.1. Overview
- 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.9.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.9.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
- 10.4.10.1. Overview
- 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.10.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.10.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
- 10.4.11.1. Overview
- 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.11.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.11.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
- 10.4.12.1. Overview
- 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.12.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.12.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.12.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
- 10.4.13.1. Overview
- 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.13.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.13.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
- 10.4.14.1. Overview
- 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.14.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.14.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
- 10.4.15.1. Overview
- 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.15.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
- 10.5.7.1. Overview
- 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.7.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.7.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
- 10.5.8.1. Overview
- 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.8.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.8.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
- 10.5.9.1. Overview
- 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.9.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.9.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
- 10.5.10.1. Overview
- 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.10.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.10.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
- 10.5.11.1. Overview
- 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.11.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
- 10.6.7.1. Overview
- 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.7.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
- 10.6.8.1. Overview
- 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.8.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
- 10.6.9.1. Overview
- 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.9.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.9.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
- 10.6.10.1. Overview
- 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.10.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.10.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
- 10.6.11.1. Overview
- 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.11.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.11.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
- 10.6.12.1. Overview
- 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.12.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.12.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
- 10.6.13.1. Overview
- 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
- 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.13.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Malaria and Sickle Cell Disease Treatment Industry
- 11.1. Competitive Dashboard
- 11.2. Company Profiles
- 11.2.1. AbbVie Inc.
- 11.2.2. Alexion Pharmaceuticals, Inc. (acquired by AstraZeneca)
- 11.2.3. Bluebird bio Inc.
- 11.2.4. Celgene Corporation (acquired by Bristol Myers Squibb)
- 11.2.5. Emmaus Pharmaceuticals, Inc.
- 11.2.6. F. Hoffmann-La Roche Ltd
- 11.2.7. Gilead Sciences, Inc.
- 11.2.8. GlaxoSmithKline plc
- 11.2.9. Johnson & Johnson
- 11.2.10. MacroGenics, Inc.
- 11.2.11. Merck & Co., Inc.
- 11.2.12. Novartis International AG
- 11.2.13. Pfizer Inc.
- 11.2.14. Sanofi S.A.
- 11.2.15. Sobi
- 11.2.16. Vertex Pharmaceuticals Incorporated
- 11.2.17. Others
12. 360 Degree Analyst View
13. Appendix
- 13.1. Research Methodology
- 13.2. References
- 13.3. Abbreviations
- 13.4. Disclaimer
- 13.5. Contact Us
